"Methotrexate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Descriptor ID |
D008727
|
MeSH Number(s) |
D03.633.100.733.631.192.500
|
Concept/Terms |
Methotrexate Sodium- Methotrexate Sodium
- Sodium, Methotrexate
- Methotrexate, Sodium Salt
- Methotrexate, Disodium Salt
|
Below are MeSH descriptors whose meaning is more general than "Methotrexate".
Below are MeSH descriptors whose meaning is more specific than "Methotrexate".
This graph shows the total number of publications written about "Methotrexate" by people in this website by year, and whether "Methotrexate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 6 | 6 |
1995 | 5 | 8 | 13 |
1996 | 2 | 9 | 11 |
1997 | 1 | 6 | 7 |
1998 | 2 | 11 | 13 |
1999 | 2 | 7 | 9 |
2000 | 3 | 4 | 7 |
2001 | 2 | 6 | 8 |
2002 | 1 | 5 | 6 |
2003 | 4 | 8 | 12 |
2004 | 4 | 8 | 12 |
2005 | 5 | 6 | 11 |
2006 | 4 | 7 | 11 |
2007 | 2 | 9 | 11 |
2008 | 2 | 13 | 15 |
2009 | 3 | 14 | 17 |
2010 | 1 | 15 | 16 |
2011 | 3 | 6 | 9 |
2012 | 1 | 6 | 7 |
2013 | 5 | 9 | 14 |
2014 | 4 | 9 | 13 |
2015 | 4 | 17 | 21 |
2016 | 1 | 6 | 7 |
2017 | 7 | 15 | 22 |
2018 | 9 | 5 | 14 |
2019 | 6 | 6 | 12 |
2020 | 2 | 6 | 8 |
2021 | 1 | 6 | 7 |
2022 | 1 | 5 | 6 |
2023 | 3 | 15 | 18 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Methotrexate" by people in Profiles.
-
Juvenile eosinophilic fasciitis: a single center case series. Pediatr Rheumatol Online J. 2024 Feb 24; 22(1):29.
-
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Feb; 204(1):123-132.
-
Methotrexate Polyglutamate Concentrations as a Possible Predictive Marker for Effectiveness of Methotrexate Therapy in Patients with Sarcoidosis: A Pilot Study. Lung. 2023 12; 201(6):617-624.
-
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2023 Dec; 24(12):1359-1374.
-
Methotrexate-based PROTACs as DHFR-specific chemical probes. Cell Chem Biol. 2024 Feb 15; 31(2):221-233.e14.
-
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):e21-e32.e4.
-
Therapeutic drug monitoring of methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther. 2023 12; 58(11-12):1151-1162.
-
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther. 2023 Dec; 29(12):770.e1-770.e6.
-
Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clin Ther. 2023 09; 45(9):e177-e186.
-
Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study. Clin Rheumatol. 2024 Jan; 43(1):103-116.